Long-term use of spironolactone for acne in women: A case series of 403 patients - 10/04/21
Abstract |
Background |
There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne.
Objective |
To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes.
Methods |
We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use.
Results |
As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50).
Limitations |
This study was conducted at a single academic medical center.
Conclusions |
Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration.
Le texte complet de cet article est disponible en PDF.Key words : acne, acne vulgaris, birth control pill, combined oral contraceptive, comprehensive acne severity scale, oral antibiotics, outcomes, spironolactone
Abbreviations used : CASS, CI, COC, PCOS
Plan
| Funding sources: Dr. Barbieri receives partial salary support through a Pfizer Fellowship grant to the Trustees of the University of Pennsylvania. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
|
| Results of this study were accepted as an abstract presentation at the Annual Society of Investigative Dermatology Meeting in May 2020 (meeting cancelled due to COVID-19) and published in the Journal of Investigative Dermatology (July 2020). |
|
| IRB approval status: Reviewed and approved by the University of Pennsylvania IRB. |
Vol 84 - N° 5
P. 1348-1355 - mai 2021 Retour au numéro
Article précédent
- Facial and neck erythema associated with dupilumab treatment: A systematic review
- Christine E. Jo, Alexandra Finstad, Jorge R. Georgakopoulos, Vincent Piguet, Jensen Yeung, Aaron M. Drucker
- The clinical spectrum of COVID-19–associated cutaneous manifestations: An Italian multicenter study of 200 adult patients
- Angelo Valerio Marzano, Giovanni Genovese, Chiara Moltrasio, Valeria Gaspari, Pamela Vezzoli, Vincenzo Maione, Cosimo Misciali, Paolo Sena, Annalisa Patrizi, Annamaria Offidani, Pietro Quaglino, Renato Arco, Marzia Caproni, Miriam Rovesti, Giorgio Bordin, Sebastiano Recalcati, Concetta Potenza, Claudio Guarneri, Gabriella Fabbrocini, Carlo Tomasini, Mariarita Sorci, Maurizio Lombardo, Paolo Gisondi, Andrea Conti, Giovanni Casazza, Ketty Peris, Piergiacomo Calzavara-Pinton, Emilio Berti, Italian Skin COVID-19 Network of the Italian Society of Dermatology and Sexually Transmitted Diseases
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?